We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Novovax Up on Rapid Progress of Coronavirus Vaccine Candidate
Read MoreHide Full Article
Novavax, Inc. (NVAX - Free Report) announced that it has identified a potential coronavirus vaccine candidate, NVX-CoV2373. The company plans to initiate a phase I study to evaluate the candidate, which has been made using the company’s proprietary nanoparticle technology, in May.
The company’s candidate has progressed well in its pre-clinical stage, which helped the company to prepare for a human clinical study weeks ahead of the previously announced schedule. For rapid development of the vaccine candidate, the company is designing the study as a phase I/II study with preliminary immunogenicity and safety data from the study anticipated in July. The phase I portion of the study will evaluate the candidate in approximately 130 patients for assessment of dosage amount and number of vaccinations.
Shares of Novavax were up 15.3% on Apr 8, following the announcement of accelerated timeline for a clinical study. In fact, the company’s shares have surged 331.7% so far this year against the industry’s decline of 9.7%. The significant increase in the company’s share price is driven by its efforts to develop a coronavirus vaccine as well as successful completion of a late-stage study on its seasonal influenza vaccine candidate, NanoFlu.
NVX-CoV2373 has shown high immunogenicity in pre-clinical studies after a single immunization. Moreover, microneutralization titers, which were already high after the first dose, increased eight-fold with the second dose. Higher the microneutralization titers, more likely is the vaccine to be protective in humans.
In March, the Coalition for Epidemic Preparedness (“CEPI”) awarded an initial funding of $4 million to support Novavax’s efforts to develop a COVID-19 vaccine. The company is in discussion with CEPI regarding additional funding to cover clinical development costs.
Novavax also has an agreement with Emergent BioSolutions (EBS - Free Report) related to manufacture and supply of GMP vaccine product for use in its clinical studies. The company believes that Emergent’s rapid deployment capabilities and expertise will help it to scale its vaccine production.
With the coronavirus pandemic infecting more than 1.5 million people worldwide and killing almost 90,000, several large and smaller pharma/biotech companies are racing against time to successfully develop a treatment or vaccine to combat the disease.
Moderna (MRNA - Free Report) is a leading player in the coronavirus vaccine field. It initiated a phase I study on its mRNA-based vaccine candidate last month. J&J (JNJ - Free Report) also announced plans to initiate a phase I clinical study on its potential coronavirus vaccine candidate in September. Translate Bio is also planning to co-develop a mRNA-based vaccine in collaboration with Sanofi.
Apart from vaccines, a few other companies are developing drugs or testing their marketed drugs in studies to treat the coronavirus disease, COVID-19. These include Gilead’s antiviral candidate remdesivir, Roche’s rheumatoid arthritis (“RA”) drug Actemra and Regeneron/Sanofi’s RA drug, Kevzara. Data from a phase III study evaluating remdesivir is expected later this month.
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
Image: Bigstock
Novovax Up on Rapid Progress of Coronavirus Vaccine Candidate
Novavax, Inc. (NVAX - Free Report) announced that it has identified a potential coronavirus vaccine candidate, NVX-CoV2373. The company plans to initiate a phase I study to evaluate the candidate, which has been made using the company’s proprietary nanoparticle technology, in May.
The company’s candidate has progressed well in its pre-clinical stage, which helped the company to prepare for a human clinical study weeks ahead of the previously announced schedule. For rapid development of the vaccine candidate, the company is designing the study as a phase I/II study with preliminary immunogenicity and safety data from the study anticipated in July. The phase I portion of the study will evaluate the candidate in approximately 130 patients for assessment of dosage amount and number of vaccinations.
Shares of Novavax were up 15.3% on Apr 8, following the announcement of accelerated timeline for a clinical study. In fact, the company’s shares have surged 331.7% so far this year against the industry’s decline of 9.7%. The significant increase in the company’s share price is driven by its efforts to develop a coronavirus vaccine as well as successful completion of a late-stage study on its seasonal influenza vaccine candidate, NanoFlu.
NVX-CoV2373 has shown high immunogenicity in pre-clinical studies after a single immunization. Moreover, microneutralization titers, which were already high after the first dose, increased eight-fold with the second dose. Higher the microneutralization titers, more likely is the vaccine to be protective in humans.
In March, the Coalition for Epidemic Preparedness (“CEPI”) awarded an initial funding of $4 million to support Novavax’s efforts to develop a COVID-19 vaccine. The company is in discussion with CEPI regarding additional funding to cover clinical development costs.
Novavax also has an agreement with Emergent BioSolutions (EBS - Free Report) related to manufacture and supply of GMP vaccine product for use in its clinical studies. The company believes that Emergent’s rapid deployment capabilities and expertise will help it to scale its vaccine production.
With the coronavirus pandemic infecting more than 1.5 million people worldwide and killing almost 90,000, several large and smaller pharma/biotech companies are racing against time to successfully develop a treatment or vaccine to combat the disease.
Moderna (MRNA - Free Report) is a leading player in the coronavirus vaccine field. It initiated a phase I study on its mRNA-based vaccine candidate last month. J&J (JNJ - Free Report) also announced plans to initiate a phase I clinical study on its potential coronavirus vaccine candidate in September. Translate Bio is also planning to co-develop a mRNA-based vaccine in collaboration with Sanofi.
Apart from vaccines, a few other companies are developing drugs or testing their marketed drugs in studies to treat the coronavirus disease, COVID-19. These include Gilead’s antiviral candidate remdesivir, Roche’s rheumatoid arthritis (“RA”) drug Actemra and Regeneron/Sanofi’s RA drug, Kevzara. Data from a phase III study evaluating remdesivir is expected later this month.
Novavax, Inc. Price
Novavax, Inc. price | Novavax, Inc. Quote
Zacks Rank
Novovax is a Zacks Rank #3 (Hold) stock currently. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.
See 8 breakthrough stocks now>>